SERVIER INDIA INTRODUCES ‘IVOSIDENIB' (TIBSOVO®), IN INDIA, FIRST-IN-CLASS TARGETED THERAPY IN ONCOLOGY FOR RARE IDH1-MUTATED AML AND CHOLANGIOCARCINOMA

Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.

- 

Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment[1], with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature, they are usually diagnosed when the disease is advanced[2].